Back
Top 0.9%
17.8%
#1
14.7%
Top 8%
11.0%
Top 1%
7.8%
Top 5%
6.0%
Top 0.7%
5.0%
Top 84%
4.2%
Top 1%
3.9%
Top 1%
2.8%
Top 6%
1.9%
Top 10%
1.9%
Top 5%
1.6%
Top 54%
1.6%
Top 8%
1.3%
Top 89%
1.3%
Top 4%
1.2%
Top 16%
1.0%
Top 2%
0.7%
Top 13%
0.7%
Top 2%
0.7%
Top 10%
0.7%
Top 7%
0.7%
Top 9%
0.5%
A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers
2022-07-03
oncology
Title + abstract only
View on medRxiv
Show abstract
Immune checkpoint blockade impedes the negative regulatory signals for T-cell response and permits more effective immune detection and eradication of cancer cells. This single-arm phase II clinical trial (ACTRN12616001019493) within the Molecular Screening and Therapeutics (MoST) program evaluates the clinical activity and safety of combination immunotherapy with durvalumab and tremelimumab in patients with advanced cancers, prioritsing rare cancers (<6 per 100,000 annual incidence) and patients...
Predicted journal destinations
1
Cancers
57 training papers
2
Clinical Cancer Research
22 training papers
3
Nature Communications
483 training papers
4
Frontiers in Oncology
34 training papers
5
eLife
262 training papers
6
British Journal of Cancer
22 training papers
7
PLOS ONE
1737 training papers
8
Cancer Medicine
17 training papers
9
BMC Cancer
21 training papers
10
Frontiers in Immunology
140 training papers
11
JAMA Network Open
125 training papers
12
Nature Medicine
88 training papers
13
BMJ Open
553 training papers
14
Nature Genetics
72 training papers
15
Scientific Reports
701 training papers
16
Journal of Clinical Investigation
50 training papers
17
Proceedings of the National Academy of Sciences
100 training papers
18
Cell Reports
25 training papers
19
iScience
74 training papers
20
International Journal of Cancer
18 training papers
21
Nature
58 training papers
22
Communications Medicine
63 training papers
23
Cell Reports Medicine
49 training papers